Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

ociated with ELND005). There are also US$60-80 million of remaining expenses associated with bapineuzumab in 2013[6] (Royalty Pharma believes there to be no apparent value in excess of the investment requirement).

Other considerations

As described elsewhere in this announcement, Royalty Pharma believes that there is a very real possibility that Elan could destroy value through its acquisition strategy.

A compelling financial propositionThe Proposal Price represents a substantial premium to comparable companies' trading multiples

The Proposal Price represents:

  • a Proposal Enterprise Value for Elan equal to 12.2x 2015E Broker Projected EBITDA (the median 2015E projected EBITDA multiple for the Specialty Pharma Companies is 5.9x[7], and for the Large Cap Biotech Companies is 9.1x);
  • a Proposal Price equal to 30.6x 2015E Broker Projected Earnings Per Share (the median 2015E projected earnings per share multiple for the Specialty Pharma Companies is 8.7x, and for the Large Cap Biotech Companies is 11.3x); and
  • a Proposal Enterprise Value for Elan equal to 8.3x 2015E Broker Projected Revenue (the median 2015E projected revenue multiple for the Specialty Pharma Companies is 2.4x and for the Large Cap Biotech Companies is 4.8x).
  • Royalty Pharma believes that it is useful to compare Elan's trading multiples with the trading multiples of other companies with acquisition-led business models similar to Elan's proposed strategy.

    For example, Royalty Pharma considers Valeant and Jazz to be successful specialty pharmaceutical companies whose business models include significant growth through acquisitions. As with Elan, these companies also have non-US tax domiciles. In contrast to Elan, Royalty Pharma believes that these companies have established operations enabling them to derive synergies from transactions.

    Valeant is trading on a 8.7x 2015E projected earnings per share multiple[8] and Jazz
    '/>"/>

    SOURCE RP Management, LLC
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
    2. Cowen Healthcare Royalty Partners Raises $1 Billion
    3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
    4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
    5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
    6. AVANIR Pharmaceuticals To participate in two conferences in March
    7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
    8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
    9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
    10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
    11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 11, 2014  Researchers have pioneered a revolutionary ... new technology, called Virtual Finger, allows scientists to ... neurons and synapses using the flat surface of ... 3D imaging studies orders of magnitude more efficient, ... level across many areas of experimental biology. The ...
    (Date:7/10/2014)... 10, 2014 Deep Knowledge Ventures ... Forum on ‘Commercialising Longevity Research’ and welcomed a ... the London Bioscience Innovation Center for the event, ... Aging Analytics Ltd. The meeting highlighted the need ... research for age-related disease, as well as the ...
    (Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
    (Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
    Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
    ... 5 DURECT Corporation,(Nasdaq: DRRX ) announced today ... 31, 2007. Total revenues were $6.6 million for the,three ... for the same,period in 2006. Net loss for the ... to a net loss of $9.8 million for the ...
    ... ST. LOUIS, Feb. 5 Monsanto Company,s ... global commercial,business, and Carl Casale, executive vice ... in separate presentations at two,conferences later this ... an update on the company,s,business performance and ...
    ... BEIJING and CLAREMONT, Calif., Feb. 5 /Xinhua-PRNewswire-FirstCall/ ... Board: KWBT) reports,on a meeting between Kiwa ... and Dr.,Xiao-Dong Huang from the Department of ... the possibility of collaboration in research and,development ...
    Cached Biology Technology:DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 4DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 5DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 6DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 7DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 8DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 9Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 2Kiwa Bio-Tech Products Group Discusses Cooperative Research With the University of Waterloo, Canada 3
    (Date:7/11/2014)... Institute of Standards and Technology (NIST) need a ... they often prove that necessity is truly the ... for M. Lorna De Leoz and Stephen Stein, ... glycomics. Glycomics is the study of the abundant, ... to proteins and lipids and influence cellular processes, ...
    (Date:7/11/2014)... July 3, 2014, Shenzhen, China Researchers from Salk ... for the first time evaluated the safety and ... and successfully developed a new method, TALEN-HDAdV, which ... pluripotent stem cell (hiPSC). This study published online ... important theoretical foundation for stem cell-based gene therapy. ...
    (Date:7/11/2014)... researchers, including scientists from the Max Planck Institute for ... major step in understanding photosynthesis, the process by which ... in its atmosphere and which is therefore crucial for ... The researchers report the first direct visualization of a ... in which a specific protein complex, photosystem II, splits ...
    Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
    ... LA JOLLA, CA---- Researchers at the Salk Institute for Biological ... skin cells and turned them into induced pluripotent stem cells ... form any other cell or tissue in the body. ... Shinya Yamanaka at Kyoto University in Japan, and human iPSCs ...
    ... Calif.) It happens in military units, street gangs ... cultures, the rituals mark the transition from adolescence to ... given. With a long history of seemingly universal ... puzzle. Why have so many cultures incorporated it into ...
    ... market to treat leukemia reversed symptoms of colitis in lab ... the University of Alberta. Faculty of Medicine & Dentistry ... journal, PLOS ONE . His team ... role in the development of colitis. When this gene quits ...
    Cached Biology News:Induced pluripotent stem cells reveal differences between humans and great apes 2Induced pluripotent stem cells reveal differences between humans and great apes 3UCSB anthropologist examines the motivating factors behind hazing 2UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3